Isoprenaline
Based on 94 publication(s) in Google Scholar
Isoprenaline is a non-selective, orally active β-adrenergic receptor agonist. Isoprenaline has potent peripheral vasodilator, bronchodilator, and cardiac stimulating activities. Isoprenaline can be used for the research of bradycardia and bronchial asthma.
For research use only. We do not sell to patients.
- Purity: 98.93%
- CAS No.: 7683-59-2
- Formula: C11H17NO3
- Molecular Weight:211.26
-
Storage:
4°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Publications Citing Use of MedChemExpress (MCE) Isoprenaline
More- Nature. 2025 Dec;648(8092):146-156. [Abstract]
- Science. 2020 Dec 4;370(6521):eaay2002. [Abstract]
- Circulation. 2018 Jun 5;137(23):2497-2513. [Abstract]
- Cancer Discov. 2026 Feb 9. [Abstract]
- Cell Mol Immunol. 2023 Feb;20(2):175-188. [Abstract]
- Sci Bull. 2024 Dec 30;69(24):3908-3924. [Abstract]
- Nat Commun. 2026 May 8;17(1):6230. [Abstract]
- Nat Commun. 2026 Jan 16;17(1):1795. [Abstract]
- Nat Commun. 2020 Sep 25;11(1):4857. [Abstract]
- ACS Nano. 2023 Nov 14;17(21):21639-21661. [Abstract]
- J Adv Res. 2024 Dec 28:S2090-1232(24)00624-6. [Abstract]
- Redox Biol. 2024 Dec 21:79:103481. [Abstract]
- Acta Pharm Sin B. 2026 Mar 14.
- J Exp Clin Cancer Res. 2019 Apr 25;38(1):174. [Abstract]
- Cell Death Differ. 2023 Mar;30(3):766-778. [Abstract]
- Chem Eng J. 2024 Sep 1.
- J Immunother Cancer. 2025 Jun 12;13(6):e011611. [Abstract]
- Phytomedicine. 2026 Jun:155:158109. [Abstract]
- J Pharm Anal. 2024 Jul;14(7):100934. [Abstract]
- Acta Pharmacol Sin. 2026 May 27. [Abstract]
- Acta Pharmacol Sin. 2025 Jun 11. [Abstract]
- J Transl Med. 2025 Jul 10;23(1):762. [Abstract]
- Biofabrication. 2022 Oct 28;15(1). [Abstract]
- ACS Appl Mater Interfaces. 2023 Oct 18;15(41):47939-47954. [Abstract]
- ACS Appl Mater Interfaces. 2023 Apr 12;15(14):17518-17531. [Abstract]
- Cell Rep. 2022 Mar 8;38(10):110468. [Abstract]
- Cell Rep. 2019 Dec 3;29(10):2929-2935.e4 [Abstract]
- Chin Med. 2024 Jun 11;19(1):82. [Abstract]
- Emerg Microbes Infect. 2025 Mar 24:2484330. [Abstract]
- Ecotoxicol Environ Saf. 2025 Nov 15:307:119433. [Abstract]
- Biochem Pharmacol. 2025 Aug 8;242(Pt 1):117218. [Abstract]
- Biochem Pharmacol. 2024 May 29:116329. [Abstract]
- Life Sci. 2026 Apr 15:391:124281. [Abstract]
- Life Sci. 2026 Mar 1:388:124212. [Abstract]
- Life Sci. 2025 Dec 15:383:124083. [Abstract]
- Food Funct. 2018 Nov 14;9(11):5528-5535. [Abstract]
- Nutrients. 2023 Mar 9;15(6):1340. [Abstract]
- Can J Cardiol. 2026 Apr 24:S0828-282X(26)00372-7. [Abstract]
- Eur J Pharmacol. 2024 Oct 30:177085. [Abstract]
- Pharmaceuticals (Basel). 2022 Jan 6;15(1):73. [Abstract]
- Eur J Pharmacol. 2021 Sep 15:907:174277. [Abstract]
- Eur J Pharmacol. 2020 Nov 5;886:173439. [Abstract]
- Int J Mol Sci. 2026 Apr 10;27(8):3425. [Abstract]
- Int Immunopharmacol. 2023 Sep 5;124(Pt A):110876. [Abstract]
- Biomolecules. 2022 Oct 27;12(11):1574. [Abstract]
- Inflammation. 2024 Apr;47(2):789-806. [Abstract]
- mBio. 2022 Dec 20;13(6):e0229722. [Abstract]
- Molecules. 2024 Feb 7;29(4):760. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2025 Dec 31;1872(3):168150. [Abstract]
- Mol Med Rep. 2026 Feb;33(2):60. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2024 Mar;1870(3):167018. [Abstract]
- Sci Rep. 2024 Jul 8;14(1):15683. [Abstract]
- Mol Cell Biochem. 2026 Jan 22. [Abstract]
- J Inflamm Res. 2023 Oct 24:16:4833-4843. [Abstract]
- Biosci Rep. 2026 May 20;46(5):BSR20250174. [Abstract]
- iScience. 2026 Jan 7;29(2):114639. [Abstract]
- iScience. 2023 Jul 22;26(9):107455. [Abstract]
- FASEB J. 2022 Mar;36(3):e22219. [Abstract]
- Curr Issues Mol Biol. 2025 Sep 26;47(10):798. [Abstract]
- Naunyn Schmiedebergs Arch Pharmacol. 2025 Mar 17. [Abstract]
- Naunyn Schmiedebergs Arch Pharmacol. 2018 Dec;391(12):1373-1385. [Abstract]
- J Tradit Complement Med. 2025 Mar 14.
- J Tradit Complement Med. 2023 Jul 12;14(1):40-54. [Abstract]
- Cell Cycle. 2021 Jul;20(13):1253-1269. [Abstract]
- J Funct Foods. 66 (2020) 1038022.
- Mol Immunol. 2025 Dec:188:45-61. [Abstract]
- Toxicol Appl Pharmacol. 2025 Oct:503:117473. [Abstract]
- Cardiovasc Drugs Ther. 2026 Jun 18. [Abstract]
- Cell Biol Int. 2021 Jan;45(1):188-197. [Abstract]
- Front Oncol. 2021 Apr 22:11:665763. [Abstract]
- Chem Biol Drug Des. 2024 Feb 6.
- Food Chem Toxicol. 2023 Apr:174:113670. [Abstract]
- Prostate. 2020 Nov;80(15):1328-1340. [Abstract]
- J Cardiovasc Transl Res. 2023 Aug;16(4):758-767. [Abstract]
- Biochem Biophys Res Commun. 2022 Feb 12:592:67-73. [Abstract]
- J Mol Cell Cardiol Plus. 2024 Dec:10:100121. [Abstract]
- Acta Pharm. 2026 Mar 25;76(1):1-12. [Abstract]
- Int J Cardiovasc Imaging. 2025 Apr 10. [Abstract]
- Biomed Res. 2023;44(3):105-115. [Abstract]
- Nat Prod Commun. 2023, 18(1): 1934578X221144581.
- bioRxiv. 2026 Jun 19.
- bioRxiv. 2025 Jul 30.
- bioRxiv. 2025 July 11.
- SSRN. 2025 May 8.
- Int J Exp Pathol. 2025 Mar;106(2):e12526. [Abstract]
- Res Sq. 2024 Sep 30.
- bioRxiv. 2024 Apr 20:2024.04.15.589650. [Abstract]
- Research Square Preprint. 2023 Sep 14.
- Research Square Preprint. 2023 Sep 14.
- Research Square Print. 2023 Feb 7.
- Biomed Pharmacother. 2021 Jul:139:111562. [Abstract]
- Biomed Pharmacother. 2021 Jun:138:111531. [Abstract]
- Research Square Preprint. 2021 Jan.
- bioRxiv. 2020 Jan.
-
IF
-
WB
-
RT-PCR
-
WB
-
WB
All Adrenergic Receptor Isoforms
MoreAll Endogenous Metabolite Isoforms
More
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| C3H 10T1/2 | EC50 |
19 nM
Compound: Isoproterenol
|
Induction of lipolysis in mouse C3H10T1/2 assessed as glycerol concentration
Induction of lipolysis in mouse C3H10T1/2 assessed as glycerol concentration
|
[PMID: 21330134] |
| C6 | EC50 |
7 nM
Compound: Isoproterenol
|
Beta adrenergic receptor agonistic activity for the stimulation of accumulation of cyclic AMP in cultured C6 glioma cells
Beta adrenergic receptor agonistic activity for the stimulation of accumulation of cyclic AMP in cultured C6 glioma cells
|
[PMID: 1672155] |
| CHO | EC50 |
0.084 nM
Compound: Isoproterenol
|
Agonistic activity was assessed by measuring cAMP accumulation in CHO cell lines expressing cloned human Beta-1 adrenergic receptor
Agonistic activity was assessed by measuring cAMP accumulation in CHO cell lines expressing cloned human Beta-1 adrenergic receptor
|
[PMID: 15603933] |
| CHO | EC50 |
0.97 nM
Compound: Isoproterenol
|
Agonistic activity was assessed by measuring cAMP accumulation in CHO cell lines expressing cloned human Beta-3 adrenergic receptor
Agonistic activity was assessed by measuring cAMP accumulation in CHO cell lines expressing cloned human Beta-3 adrenergic receptor
|
[PMID: 15603933] |
| CHO | EC50 |
2 nM
Compound: Isoproterenol
|
Agonistic activity was assessed by measuring cAMP accumulation in CHO cell lines expressing cloned human Beta-2 adrenergic receptor
Agonistic activity was assessed by measuring cAMP accumulation in CHO cell lines expressing cloned human Beta-2 adrenergic receptor
|
[PMID: 15603933] |
| CHO | EC50 |
3.9 nM
Compound: isoproterenol
|
Agonist activity at human adrenergic beta3 receptor expressed in CHO cells assessed as [3H]cAMP levels by radiolabeled ligand based assay
Agonist activity at human adrenergic beta3 receptor expressed in CHO cells assessed as [3H]cAMP levels by radiolabeled ligand based assay
|
[PMID: 18083578] |
| CHO | EC50 |
5.8 nM
Compound: isoproterenol
|
Agonist activity at human adrenergic beta-3 receptor expressed in CHO cells assessed as cAMP levels by DELFIA method
Agonist activity at human adrenergic beta-3 receptor expressed in CHO cells assessed as cAMP levels by DELFIA method
|
[PMID: 18083578] |
| CHO | EC50 |
0.084 nM
Compound: ISP
|
Agonist activity at human beta-1 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by EIA
Agonist activity at human beta-1 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by EIA
|
[PMID: 18307290] |
| CHO | EC50 |
0.97 nM
Compound: ISP
|
Agonist activity at human beta3 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by EIA
Agonist activity at human beta3 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by EIA
|
[PMID: 18307290] |
| CHO | EC50 |
0.084 nM
Compound: ISP
|
Agonist activity at human recombinant beta-1 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by enzyme immuno assay
Agonist activity at human recombinant beta-1 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by enzyme immuno assay
|
[PMID: 18553954] |
| CHO | EC50 |
0.97 nM
Compound: ISP
|
Agonist activity at human recombinant beta3 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by enzyme immuno assay
Agonist activity at human recombinant beta3 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by enzyme immuno assay
|
[PMID: 18553954] |
| CHO | EC50 |
2 nM
Compound: ISP
|
Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by enzyme immuno assay
Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by enzyme immuno assay
|
[PMID: 18553954] |
| CHO | EC50 |
0.084 nM
Compound: ISP
|
Agonist activity at human cloned beta-1 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation
Agonist activity at human cloned beta-1 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation
|
[PMID: 18651730] |
| CHO | EC50 |
0.97 nM
Compound: ISP
|
Agonist activity at human cloned beta3 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation
Agonist activity at human cloned beta3 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation
|
[PMID: 18651730] |
| CHO | EC50 |
2 nM
Compound: ISP
|
Agonist activity at human beta2 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation
Agonist activity at human beta2 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation
|
[PMID: 18651730] |
| CHO | EC50 |
0.084 nM
Compound: ISP
|
Agonist activity at human cloned adrenergic beta-1 receptor expressed in CHO cells assessed as cAMP accumulation
Agonist activity at human cloned adrenergic beta-1 receptor expressed in CHO cells assessed as cAMP accumulation
|
[PMID: 18752946] |
| CHO | EC50 |
0.97 nM
Compound: ISP
|
Agonist activity at human cloned adrenergic beta3 receptor expressed in CHO cells assessed as cAMP accumulation
Agonist activity at human cloned adrenergic beta3 receptor expressed in CHO cells assessed as cAMP accumulation
|
[PMID: 18752946] |
| CHO | EC50 |
0.003 μM
Compound: ISO
|
Agonist activity at human cloned adrenergic beta2 receptor expressed in CHO cells assessed as increase in cAMP production after 2 days by radioimmunoassay
Agonist activity at human cloned adrenergic beta2 receptor expressed in CHO cells assessed as increase in cAMP production after 2 days by radioimmunoassay
|
[PMID: 19232786] |
| CHO | EC50 |
0.012 μM
Compound: ISO
|
Agonist activity at human cloned adrenergic beta-1 receptor expressed in CHO cells assessed as increase in cAMP production after 2 days by radioimmunoassay
Agonist activity at human cloned adrenergic beta-1 receptor expressed in CHO cells assessed as increase in cAMP production after 2 days by radioimmunoassay
|
[PMID: 19232786] |
| CHO | EC50 |
0.1 μM
Compound: ISO
|
Agonist activity at human cloned adrenergic beta3 receptor expressed in CHO cells assessed as increase in cAMP production after 2 days by radioimmunoassay
Agonist activity at human cloned adrenergic beta3 receptor expressed in CHO cells assessed as increase in cAMP production after 2 days by radioimmunoassay
|
[PMID: 19232786] |
| CHO | EC50 |
0.003 μM
Compound: ISO
|
Agonist activity at human beta2 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation
Agonist activity at human beta2 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation
|
[PMID: 19362005] |
| CHO | EC50 |
0.012 μM
Compound: ISO
|
Agonist activity at human beta3 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation
Agonist activity at human beta3 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation
|
[PMID: 19362005] |
| CHO | EC50 |
0.1 μM
Compound: ISO
|
Agonist activity at human beta-1 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation
Agonist activity at human beta-1 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation
|
[PMID: 19362005] |
| CHO | EC50 |
0.84 nM
Compound: ISP
|
Agonist activity at human recombinant beta-1 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by enzyme immunoassay
Agonist activity at human recombinant beta-1 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by enzyme immunoassay
|
[PMID: 19366244] |
| CHO | EC50 |
0.97 nM
Compound: ISP
|
Agonist activity at human recombinant beta3 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by enzyme immunoassay
Agonist activity at human recombinant beta3 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by enzyme immunoassay
|
[PMID: 19366244] |
| CHO | EC50 |
2 nM
Compound: ISP
|
Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by enzyme immunoassay
Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by enzyme immunoassay
|
[PMID: 19366244] |
| CHO | EC50 |
0.003 μM
Compound: ISO
|
Agonist activity at human cloned adrenergic beta2 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay
Agonist activity at human cloned adrenergic beta2 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay
|
[PMID: 19581100] |
| CHO | EC50 |
0.012 μM
Compound: ISO
|
Agonist activity at human cloned adrenergic beta-1 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay
Agonist activity at human cloned adrenergic beta-1 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay
|
[PMID: 19581100] |
| CHO | EC50 |
0.1 μM
Compound: ISO
|
Agonist activity at human cloned adrenergic beta3 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay
Agonist activity at human cloned adrenergic beta3 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay
|
[PMID: 19581100] |
| CHO | EC50 |
1 μM
Compound: ISO
|
Agonist activity at human cloned adrenergic beta-1 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay relative to isoproterenol
Agonist activity at human cloned adrenergic beta-1 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay relative to isoproterenol
|
[PMID: 19581100] |
| CHO | EC50 |
1 μM
Compound: ISO
|
Agonist activity at human cloned adrenergic beta2 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay relative to isoproterenol
Agonist activity at human cloned adrenergic beta2 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay relative to isoproterenol
|
[PMID: 19581100] |
| CHO | EC50 |
1 μM
Compound: ISO
|
Agonist activity at human cloned adrenergic beta3 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay relative to isoproterenol
Agonist activity at human cloned adrenergic beta3 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay relative to isoproterenol
|
[PMID: 19581100] |
| CHO | EC50 |
0.84 nM
Compound: ISP
|
Agonist activity at human recombinant adrenergic beta2 receptor expressed in CHO cells assessed as stimulation of cAMP level after 1 hr by enzyme immunoassay
Agonist activity at human recombinant adrenergic beta2 receptor expressed in CHO cells assessed as stimulation of cAMP level after 1 hr by enzyme immunoassay
|
[PMID: 19608416] |
| CHO | EC50 |
2 nM
Compound: ISP
|
Agonist activity at human recombinant adrenergic beta3 receptor expressed in CHO cells assessed as stimulation of cAMP level after 1 hr by enzyme immunoassay
Agonist activity at human recombinant adrenergic beta3 receptor expressed in CHO cells assessed as stimulation of cAMP level after 1 hr by enzyme immunoassay
|
[PMID: 19608416] |
| CHO | EC50 |
86 nM
Compound: isoproterenol
|
Agonist activity at human recombinant beta3-adrenergic receptor expressed in CHO cells assessed as increase of cAMP level after 30 mins
Agonist activity at human recombinant beta3-adrenergic receptor expressed in CHO cells assessed as increase of cAMP level after 30 mins
|
[PMID: 26125514] |
| HEK293 | EC50 |
0.2 nM
Compound: Isoproterenol
|
Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as stimulation of cAMP accumulation
Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as stimulation of cAMP accumulation
|
[PMID: 24326276] |
| HEK293 | EC50 |
120 nM
Compound: Isoprenaline
|
Agonist activity at PK-tagged beta2 receptor (unknown origin) transfected in HEK293 cells after 90 mins by beta-arrestin assay
Agonist activity at PK-tagged beta2 receptor (unknown origin) transfected in HEK293 cells after 90 mins by beta-arrestin assay
|
[PMID: 27132867] |
| HEK293 | EC50 |
87 nM
Compound: Isoprenaline
|
Agonist activity at human beta2 receptor expressed in HEK293 cells cotransfected with Gqs5 protein assessed as [3H]IP3 accumulation after 120 mins by scintillation counting assay in presence of myo-[3H]-inositol
Agonist activity at human beta2 receptor expressed in HEK293 cells cotransfected with Gqs5 protein assessed as [3H]IP3 accumulation after 120 mins by scintillation counting assay in presence of myo-[3H]-inositol
|
[PMID: 27132867] |
| Sf21 | IC50 |
>1000 μM
Compound: Isoproterenol
|
Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
|
[PMID: 21965623] |
| Sf21 | IC50 |
>1000 μM
Compound: Isoproterenol
|
Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
|
[PMID: 21965623] |
Isoprenaline (300 nM, 3 min) increases particulate cGMP- and cilostamide-inhibited, low-Km cAMP phosphodiesterase (cAMP-PDE) activity by about 100% in intact rat fat cells[1].
Isoprenaline inhibits insulin-stimulated glucose transport activity in rat adipocytes. Isoprenaline, in the absence of adenosine, promotes a time-dependent (t1/2 approximately 2 min) decrease in the accessibility of insulin-stimulated cell surface GLUT4 of > 50%, which directly correlated with the observed inhibition of transport activity[2].
Isoprenaline (5 nM and 10 μM) increases cyclic AMP levels and this effect is potentiated by cilostamide (10 mM), by rolipram, a cyclic AMP-specific PDE (PDE 4) inhibitor (10 mM) and by cyclic GMP-elevating agents (50 nM ANF or 30 nM SNP plus 100 nM DMPPO)[3].
Isoprenaline increases the transcriptional activity of Gi alpha-2 gene to 140% of the control value, whereas gene specific hybridization for Gs alpha remains unchanged[4].
Isoprenaline (20 nM) increases the amplitude of total iK and causes a negative shift of approximately 10 mV in the activation curve for iK, both in the absence and in the presence of 300 nM nisoldipine to block the L-type Ca2+ current[5].
Isoprenaline (20 nM) increases the spontaneous pacemaker rate of sino-atrial node pacemaker cells by 16% in rabbit isolated pacemaker cells[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Dogs[1]
-
Dosage:0.27-0. 64 μg/kg
-
Administration:oral
-
Result:Excreted largely unchanged in urine, only one-third of the radioactivity in urine was in the form of the O-methyl metabolite.
Showed plasma radioactivity was almost entirely as conjugated isoprenaline and this metabolite accounted for more than 80% of radioactivity in urine.
. Showed heart rate returned to base-line values when high plasma concentrations.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 7683-59-2
-
Appearance Solid
-
Molecular Weight 211.26
-
Formula C11H17NO3
-
Color Light brown to brown
-
SMILES
OC1=CC=C(C(O)CNC(C)C)C=C1O
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Publications (94)
-
Journal Impact Factor
-
Most Recent
-
Nature
2025 Dec;648(8092):146-156. PMID: 41094146 -
Science
2020 Dec 4;370(6521):eaay2002. PMID: 33093214 -
Circulation
Targeting Chondroitin Sulfate Glycosaminoglycans to Treat Cardiac Fibrosis in Pathological Remodeling. [Abstract]2018 Jun 5;137(23):2497-2513. PMID: 29371215 -
Cancer Discov
Myofibroblasts Induce Neuroplasticity to Promote Pancreatic Inflammation and Cancer Progression. [Abstract]2026 Feb 9. PMID: 41661076 -
Cell Mol Immunol
β-adrenoreceptor-triggered PKA activation negatively regulates the innate antiviral response. [Abstract]2023 Feb;20(2):175-188. PMID: 36600052
Isoprenaline purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2023 Feb;20(2):175-188. [Abstract]
Isoprenaline hydrochloride (ISO; 10 μM; 6 h), markedly inhibits SeV- or HSV-1-induced transcription of the IFNB1 and CXCL10 genes in THP1 cells.
Isoprenaline purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2023 Feb;20(2):175-188. [Abstract]
Isoprenaline hydrochloride (ISO; 10 μM; 0, 3, 6, 9 h) inhibits the phosphorylation of MITAS366, IRF3S386 and STAT1Y701 induced by HSV-1, HSV-2 and HCMV, as well as the phosphorylation of IRF3S386 and STAT1Y701 induced by SeV, EMCV and VSV, in THP1 cells.
-
Sci Bull
Restoring sweat gland function in mice using regenerative sweat gland cells derived from chemically reprogrammed human epidermal keratinocytes. [Abstract]2024 Dec 30;69(24):3908-3924. PMID: 39550273 -
Nat Commun
Disrupting sympathetic nerve-tumor crosstalk via biomimetic nanovesicles to augment chemotherapy efficacy under chronic stress. [Abstract]2026 May 8;17(1):6230. PMID: 42103759 -
Nat Commun
An artificial cell capable of signal transduction mediated by ADRB2 for the regulation of glycogenolysis. [Abstract]2026 Jan 16;17(1):1795. PMID: 41545427 -
Nat Commun
DeSiphering receptor core-induced and ligand-dependent conformational changes in arrestin via genetic encoded trimethylsilyl 1H-NMR probe. [Abstract]2020 Sep 25;11(1):4857. PMID: 32978402 -
ACS Nano
Red Blood Cell-Derived Extracellular Vesicles Display Endogenous Antiviral Effects and Enhance the Efficacy of Antiviral Oligonucleotide Therapy. [Abstract]2023 Nov 14;17(21):21639-21661. PMID: 37852618 -
J Adv Res
Elevated EBF2 in mouse but not pig drives the progressive brown fat lineage specification via chromatin activation. [Abstract]2024 Dec 28:S2090-1232(24)00624-6. PMID: 39736442 -
Redox Biol
2024 Dec 21:79:103481. PMID: 39721495 -
-
J Exp Clin Cancer Res
Mammalian Eps15 homology domain 1 potentiates angiogenesis of non-small cell lung cancer by regulating β2AR signaling. [Abstract]2019 Apr 25;38(1):174. PMID: 31023336
Isoprenaline purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2019 Apr 25;38(1):174. [Abstract]
EHD1 stabilizes β2AR. A549 cells are incubated in serum-free 1640 medium for 16 h and then treated with ISO (10 μM) for the indicated times in the presence of cycloheximide (CHX, 20 μg/mL). The cell lysates are analyzed by Western blot.
Isoprenaline purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2019 Apr 25;38(1):174. [Abstract]
A549 cells were transfected with vector or ShEHD1 and then treated with DMSO or ISO (Isoprenaline) (10 μM; 16 h), and the EHD1 and VEGFA protein levels were assessed by immunoblotting.
-
Cell Death Differ
Blockage of PPARγ T166 phosphorylation enhances the inducibility of beige adipocytes and improves metabolic dysfunctions. [Abstract]2023 Mar;30(3):766-778. PMID: 36329235
Isoprenaline purchased from MedChemExpress. Usage Cited in: Cell Death Differ. 2023 Mar;30(3):766-778. [Abstract]
SVF differentiated adipocytes were treated with 2 μM isoprenaline (ISO) for 12h followed by Q-PCR analysis of browning genes (n=3). Gene expression is normalized to the 36B4 endogenous control.
-
Isoprenaline purchased from MedChemExpress. Usage Cited in: Chem Eng J. 2024 Sep 1.
Isoprenaline administration significantly reduces [email protected] anti-inflammatory and antioxidant activities.
Isoprenaline purchased from MedChemExpress. Usage Cited in: Chem Eng J. 2024 Sep 1.
Isoprenaline significantly activates ERK1/2-induced DRP1 phosphorylation on serine 616 (pDRP1).
-
J Immunother Cancer
ADRB2 inhibition suppresses cancer immune evasion by regulating tumor SOX10-PD-L1 axis and T cell function. [Abstract]2025 Jun 12;13(6):e011611. PMID: 40514069 -
Phytomedicine
Wendan tablet and its active component isocurcumenol protect against myocardial ischemia via targeting ALOX15 and inhibiting lipid peroxidation. [Abstract]2026 Jun:155:158109. PMID: 41966026 -
J Pharm Anal
Baicalin reduces chronic stress-induced breast cancer metastasis via directly targeting β2-adrenergic receptor. [Abstract]2024 Jul;14(7):100934. PMID: 39139999 -
Acta Pharmacol Sin
The solute carrier transporter SLCO5A1 as a novel therapeutic target for the treatment of myocardial infarction-induced heart failure. [Abstract]2026 May 27. PMID: 42204299 -
Acta Pharmacol Sin
YOD1 mediates isoproterenol-induced cardiac remodeling by deubiquitinating PKM2 and reducing PKM2 tetramerization in cardiomyocytes. [Abstract]2025 Jun 11. PMID: 40500343 -
J Transl Med
Gut microbiota dysbiosis exacerbates heart failure by the LPS-TLR4/NF-κB signalling axis: mechanistic insights and therapeutic potential of TLR4 inhibition. [Abstract]2025 Jul 10;23(1):762. PMID: 40640887 -
Biofabrication
Heart-on-a-chip using human iPSC-derived cardiomyocytes with integrated vascular endothelial layer based on culture patch as a potential platform for drug evaluation. [Abstract]2022 Oct 28;15(1). PMID: 36195063 -
ACS Appl Mater Interfaces
Insights into the Mechanism of Supramolecular Self-Assembly in the Astragalus membranaceus- Angelica sinensis Codecoction. [Abstract]2023 Oct 18;15(41):47939-47954. PMID: 37791782 -
ACS Appl Mater Interfaces
Aligned Nanofibrous Net Deposited Perpendicularly on Microridges Supports Endothelium Formation and Promotes the Structural Maturation of hiPSC-Derived Cardiomyocytes. [Abstract]2023 Apr 12;15(14):17518-17531. PMID: 36992621 -
Cell Rep
Moderate heart rate reduction promotes cardiac regeneration through stimulation of the metabolic pattern switch. [Abstract]2022 Mar 8;38(10):110468. PMID: 35263588 -
Cell Rep
2019 Dec 3;29(10):2929-2935.e4 PMID: 31801060 -
Chin Med
Xinbao Pill ameliorates heart failure via regulating the SGLT1/AMPK/PPARα axis to improve myocardial fatty acid energy metabolism. [Abstract]2024 Jun 11;19(1):82. PMID: 38862959 -
Emerg Microbes Infect
Unique immune and other responses of human nasal epithelial cells infected with H5N1 avian influenza virus compared to seasonal human influenza A and B viruses. [Abstract]2025 Mar 24:2484330. PMID: 40126073 -
Ecotoxicol Environ Saf
PPARγ-responsive luciferase reporter system for high-throughput screening of chemical toxins with potential pulmonary fibrosis effects. [Abstract]2025 Nov 15:307:119433. PMID: 41273832 -
Biochem Pharmacol
2025 Aug 8;242(Pt 1):117218. PMID: 40784571 -
Biochem Pharmacol
FGF13 deficiency ameliorates calcium signaling abnormality in heart failure by regulating microtubule stability. [Abstract]2024 May 29:116329. PMID: 38821375 -
Life Sci
Oxytocin ameliorates cardiac hypertrophy by inhibiting mitochondrial dysfunction and pyroptosis via AMPK/PGC-1α /TFAM pathway. [Abstract]2026 Apr 15:391:124281. PMID: 41722768 -
Life Sci
iNKT cell activation exacerbates isoproterenol-induced cardiac injury through macrophage IFN-γ-STAT1 signaling. [Abstract]2026 Mar 1:388:124212. PMID: 41539464 -
Life Sci
Dapagliflozin attenuates post-infarction fibrosis via cardiomyocyte protection and fibroblast inhibition. [Abstract]2025 Dec 15:383:124083. PMID: 41224193 -
Food Funct
Correlation of drug-induced and drug-related ultra-high performance liquid chromatography-mass spectrometry serum metabolomic profiles yields discovery of effective constituents of Sini decoction against myocardial ischemia in rats. [Abstract]2018 Nov 14;9(11):5528-5535. PMID: 30209468 -
Nutrients
Naringenin Attenuates Isoprenaline-Induced Cardiac Hypertrophy by Suppressing Oxidative Stress through the AMPK/NOX2/MAPK Signaling Pathway. [Abstract]2023 Mar 9;15(6):1340. PMID: 36986070 -
Can J Cardiol
Canagliflozin Alleviates Pressure Overload-Induced Cardiac Dysfunction via PINK1 Regulation by Inhibiting Mitophagy-Driven Ferroptosis. [Abstract]2026 Apr 24:S0828-282X(26)00372-7. PMID: 42035950 -
Eur J Pharmacol
miR-421-mediated suppression of FGF13 as a novel mechanism ameliorates cardiac hypertrophy by inhibiting endoplasmic reticulum stress. [Abstract]2024 Oct 30:177085. PMID: 39486770 -
Pharmaceuticals (Basel)
2022 Jan 6;15(1):73. PMID: 35056130 -
Eur J Pharmacol
Protective effects of dioscin against isoproterenol-induced cardiac hypertrophy via adjusting PKCε/ERK-mediated oxidative stress. [Abstract]2021 Sep 15:907:174277. PMID: 34171391 -
Eur J Pharmacol
Tempol prevents isoprenaline-induced takotsubo syndrome via the reactive oxygen species/mitochondrial/anti-apoptosis /p38 MAPK pathway. [Abstract]2020 Nov 5;886:173439. PMID: 32871175 -
Int J Mol Sci
2026 Apr 10;27(8):3425. PMID: 42074068 -
Int Immunopharmacol
Germacrone mitigates cardiac remodeling by regulating PI3K/AKT-mediated oxidative stress, inflammation, and apoptosis. [Abstract]2023 Sep 5;124(Pt A):110876. PMID: 37683399 -
Biomolecules
Inhibition of Wdr5 Attenuates Ang-II-Induced Fibroblast-to-Myofibroblast Transition in Cardiac Fibrosis by Regulating Mdm2/P53/P21 Pathway. [Abstract]2022 Oct 27;12(11):1574. PMID: 36358925 -
Inflammation
2024 Apr;47(2):789-806. PMID: 38446361 -
mBio
Grass Carp Reovirus Induces Formation of Lipid Droplets as Sites for Its Replication and Assembly. [Abstract]2022 Dec 20;13(6):e0229722. PMID: 36445081 -
Molecules
Chlorogenic Acid Attenuates Isoproterenol Hydrochloride-Induced Cardiac Hypertrophy in AC16 Cells by Inhibiting the Wnt/β-Catenin Signaling Pathway. [Abstract]2024 Feb 7;29(4):760. PMID: 38398512 -
Biochim Biophys Acta Mol Basis Dis
Osteopontin aggravates myocardial fibrosis by promoting phenotypic transition of cardiac fibroblasts via Hippo-YAP pathway. [Abstract]2025 Dec 31;1872(3):168150. PMID: 41478364 -
Mol Med Rep
ABCC9 knockdown attenuates isoproterenol‑induced myocardial hypertrophy by inhibiting the PI3K/AKT signaling pathway. [Abstract]2026 Feb;33(2):60. PMID: 41347799 -
Biochim Biophys Acta Mol Basis Dis
OTUD1 promotes isoprenaline- and myocardial infarction-induced heart failure by targeting PDE5A in cardiomyocytes. [Abstract]2024 Mar;1870(3):167018. PMID: 38185350 -
Sci Rep
Empagliflozin rescues pro-arrhythmic and Ca2+ homeostatic effects of transverse aortic constriction in intact murine hearts. [Abstract]2024 Jul 8;14(1):15683. PMID: 38977794 -
Mol Cell Biochem
Identification of disease-associated gene expression signatures for mechanistic insights and drug prediction in dilated cardiomyopathy-induced heart failure. [Abstract]2026 Jan 22. PMID: 41569495 -
J Inflamm Res
Creation of a Rat Takotsubo Syndrome Model and Utilization of Machine Learning Algorithms for Screening Diagnostic Biomarkers. [Abstract]2023 Oct 24:16:4833-4843. PMID: 37901384 -
Biosci Rep
Isoprenaline alleviates diabetic kidney disease via multi-target inhibition of the cGAS-STING pathway. [Abstract]2026 May 20;46(5):BSR20250174. PMID: 41795784 -
iScience
Thrombospondin 1 aggravates cardiac remodeling in heart failure with preserved ejection fraction by inhibiting mitophagy. [Abstract]2026 Jan 7;29(2):114639. PMID: 41623478 -
iScience
Region-specific sympatho-adrenergic regulation of specialized vasculature in bone homeostasis and regeneration. [Abstract]2023 Jul 22;26(9):107455. PMID: 37680481 -
FASEB J
RNA-binding protein YBX1 promotes brown adipogenesis and thermogenesis via PINK1/PRKN-mediated mitophagy. [Abstract]2022 Mar;36(3):e22219. PMID: 35195911 -
Curr Issues Mol Biol
Cinnamomum migao H.W. Li Ethanol-Water Extract Suppresses IL-6 Production in Cardiac Fibroblasts: Mechanisms Elucidated via UPLC-Q-TOF-MS, Network Pharmacology, and Experimental Assays. [Abstract]2025 Sep 26;47(10):798. PMID: 41150746 -
Naunyn Schmiedebergs Arch Pharmacol
2025 Mar 17. PMID: 40095050 -
Naunyn Schmiedebergs Arch Pharmacol
Protocatechuic aldehyde protects against isoproterenol-induced cardiac hypertrophy via inhibition of the JAK2/STAT3 signaling pathway. [Abstract]2018 Dec;391(12):1373-1385. PMID: 30132020
Isoprenaline purchased from MedChemExpress. Usage Cited in: Naunyn Schmiedebergs Arch Pharmacol. 2018 Dec;391(12):1373-1385. [Abstract]
NRCMs are pre-incubated with PCA (50, 100, and 200 μM) for 1 h followed by 10 μM Isoproterenol (ISO) treatment. Cell surface area is measured by rhodamine-phalloidin staining. The expression of β-MHC is detected by Western blot.
-
-
J Tradit Complement Med
Zhilong Huoxue Tongyu capsule alleviates myocardial fibrosis by improving endothelial cell dysfunction. [Abstract]2023 Jul 12;14(1):40-54. PMID: 38223805 -
Cell Cycle
Quercetin prevents isoprenaline-induced myocardial fibrosis by promoting autophagy via regulating miR-223-3p/FOXO3. [Abstract]2021 Jul;20(13):1253-1269. PMID: 34097559 -
-
Mol Immunol
Plasma secretory protein genes in hepatocellular carcinoma and heart failure: Comorbidity and biological function exploration. [Abstract]2025 Dec:188:45-61. PMID: 41192015 -
Toxicol Appl Pharmacol
2025 Oct:503:117473. PMID: 40653114 -
Cardiovasc Drugs Ther
Shenfu Injection Inhibits Cardiac Fibroblast Activation and Improves Myocardial Fibrosis by Down-regulating M1 Macrophage-Derived Exosomal miR-155-5p. [Abstract]2026 Jun 18. PMID: 42313305 -
Cell Biol Int
Bone marrow mesenchymal stem cells inhibit cardiac hypertrophy by enhancing FoxO1 transcription. [Abstract]2021 Jan;45(1):188-197. PMID: 33049085 -
Front Oncol
2021 Apr 22:11:665763. PMID: 33968771 -
-
Food Chem Toxicol
1,3-dichloro-2-propanol caused lipid droplets accumulation by suppressing neutral lipases via BMAL1 in hepatocytes. [Abstract]2023 Apr:174:113670. PMID: 36805544
Isoprenaline purchased from MedChemExpress. Usage Cited in: Food Chem Toxicol. 2023 Apr:174:113670. [Abstract]
Isoprenaline hydrochloride (ISO; 10 μM; 6 h) pretreatment markedly restores the ATGL and HSL expressions decreased by 1,3-dichloro-2-propanol (1,3-DCP; 100 μM; 6 h) in HepG2 cells.
-
Prostate
β2 -adrenergic receptor signaling drives prostate cancer progression by targeting the Sonic hedgehog-Gli1 signaling activation. [Abstract]2020 Nov;80(15):1328-1340. PMID: 32894788 -
J Cardiovasc Transl Res
2023 Aug;16(4):758-767. PMID: 36715820 -
Biochem Biophys Res Commun
2022 Feb 12:592:67-73. PMID: 35032834 -
J Mol Cell Cardiol Plus
Dual calcium-voltage optical mapping of regional voltage and calcium signals in intact murine RyR2-R2474S hearts. [Abstract]2024 Dec:10:100121. PMID: 39697246 -
Acta Pharm
The effect of astragaloside IV on a model of isoproterenol-induced hypertrophic injury in H9c2 cells. [Abstract]2026 Mar 25;76(1):1-12. PMID: 41885696 -
Int J Cardiovasc Imaging
Assessment of left ventricular systolic function and pathological changes using layer-specific strain in rats with myocardial hypertrophy at various disease stages. [Abstract]2025 Apr 10. PMID: 40208430 -
Biomed Res
The lncRNA ADAMTS9-AS1/miR-185-5p/KAT7 ceRNA network inhibits cardiomyocyte hypertrophy in hypertrophic obstructive cardiomyopathy. [Abstract]2023;44(3):105-115. PMID: 37258203 -
-
-
-
-
-
Int J Exp Pathol
KLF9 aggravates the cardiomyocyte hypertrophy in hypertrophic obstructive cardiomyopathy through the lncRNA UCA1/p27 axis. [Abstract]2025 Mar;106(2):e12526. PMID: 39909852 -
-
bioRxiv
Functional cardiac consequences of β-adrenergic stress-induced injury in the mdx mouse model of Duchenne muscular dystrophy. [Abstract]2024 Apr 20:2024.04.15.589650. PMID: 38659739 -
-
-
-
Biomed Pharmacother
Periplocymarin protects against myocardial fibrosis induced by β-adrenergic activation in mice. [Abstract]2021 Jul:139:111562. PMID: 33839492 -
Biomed Pharmacother
Compound Danshen Dripping Pill inhibits doxorubicin or isoproterenol-induced cardiotoxicity. [Abstract]2021 Jun:138:111531. PMID: 34311530 -
-
Solvent & Solubility
DMSO : 10 mg/mL (47.34 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Degerman E, et al. Evidence that insulin and isoprenaline activate the cGMP-inhibited low-Km cAMP phosphodiesterase in rat fat cells by phosphorylation. Proc Natl Acad Sci U S A. 1990 Jan;87(2):533-7. [Content Brief]
[2]. Vannucci SJ, et al. Cell surface accessibility of GLUT4 glucose transporters in insulin-stimulated rat adipose cells. Modulation by isoprenaline and adenosine. Biochem J. 1992 Nov 15;288 (Pt 1):325-30. [Content Brief]
[3]. Delpy E, et al. Effects of cyclic GMP elevation on isoprenaline-induced increase in cyclic AMP and relaxation in rat aortic smooth muscle: role of phosphodiesterase 3. Br J Pharmacol. 1996 Oct;119(3):471-8. [Content Brief]
[4]. Muller FU, et al. Isoprenaline stimulates gene transcription of the inhibitory G protein alpha-subunit Gi alpha-2 in rat heart. Circ Res. 1993 Mar;72(3):696-700. [Content Brief]
[5]. Lei M, et al. Modulation of delayed rectifier potassium current, iK, by isoprenaline in rabbit isolated pacemaker cells. Exp Physiol. 2000 Jan;85(1):27-35. [Content Brief]
[6]. M E Conolly, et al. Metabolism of isoprenaline in dog and man. Br J Pharmacol [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.7335 mL | 23.6675 mL | 47.3350 mL | 118.3376 mL |
| 5 mM | 0.9467 mL | 4.7335 mL | 9.4670 mL | 23.6675 mL | |
| 10 mM | 0.4734 mL | 2.3668 mL | 4.7335 mL | 11.8338 mL | |
| 15 mM | 0.3156 mL | 1.5778 mL | 3.1557 mL | 7.8892 mL | |
| 20 mM | 0.2367 mL | 1.1834 mL | 2.3668 mL | 5.9169 mL | |
| 25 mM | 0.1893 mL | 0.9467 mL | 1.8934 mL | 4.7335 mL | |
| 30 mM | 0.1578 mL | 0.7889 mL | 1.5778 mL | 3.9446 mL | |
| 40 mM | 0.1183 mL | 0.5917 mL | 1.1834 mL | 2.9584 mL |